BeOne Medicines share price logo

BeOne Medicines

NASDAQ: ONC

Large Cap

$413.08

-3.46

(-0.83%)

Live

as on

BeOne Medicines Stock Performance

as on November 17, 2026 at 7:34 am IST

  • Day's Low

    Day's High

    $411.87
    $418.35
    downward going graph

    0.29%

    Downside

    1.28%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $253.95
    $424.73
    downward going graph

    38.52%

    Downside

    2.82%

    Upside

    downward going graph

BeOne Medicines share price movements today

Previous Close
$416.54
Open
$416.83
Volume
101.5K
Market Cap
$47.6B
Day's Low - High
$411.87 - $418.35
52 Week Low - High
$253.95 - $424.73

BeOne Medicines Historical Returns

1 Month Return
+ 12.87 %
3 Month Return
+ 19.87 %
1 Year Return
+ 13.86 %
3 Year Return
0 %
5 Year Return
0 %

BeOne Medicines Stock Fundamentals & Key Indicators

Check BeOne Medicines market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$47.6B

EPS (TTM)

65.26

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

2.12%

PE Ratio (TTM)

67.06

Industry PE ratio

7.76

PEG Ratio

-0.74

EBITDA

1.4B

Revenue (TTM)

6.6B

Profit Margin

88.39%

Return On Equity TTM

18.24%

BeOne Medicines vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of BeOne Medicines with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$47.6BNA67.0688.39%0.00%
Neutral$100.6B0.07%-35.1828.00%0.00%
StrongBuy$136.6B185.99%34.3985.57%0.00%
Buy$98.8B48.65%20.3585.77%0.39%

Stock Returns calculator for BeOne Medicines Stock including INR - Dollar returns

The BeOne Medicines stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

BeOne Medicines investment value today

Current value as on today

₹1,19,654

Returns

₹19,654

(+19.65%)

Returns from BeOne Medicines Stock

₹12,919 (+12.92%)

Dollar Impact

₹6,735 (+6.73%)

Analyst Recommendation on BeOne Medicines Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for BeOne Medicines. Average target price of $455.662

BeOne Medicines Share Price Target

Get share price movements and forecasts by analysts on BeOne Medicines.

Current Price

$413.08

Analyzed by

10 Analysts

High

$477

0

Low

$430

BeOne Medicines target price $0, a slight upside of 0% compared to current price of $413.08. According to 10 analysts rating.

Indian Investors' Interest in BeOne Medicines Stock

Search interest for BeOne Medicines Stock has increased by 165% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:165% versus previous 30 day period

BeOne Medicines Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
929
1,001
1,127
1,117
1,315
1,412
1,498
1,513
1,705
1,889
Gross Profit
791
831
967
952
1,150
1,215
1,355
1,346
1,530
1,672
Operating Income
-107
-120
-79
11
87
163
185
249
325
418
EBITDA
-80
-27
-35
60
135
184
248
333
392
452
Interest Expense
-
-
-
7
-
-
-
32
39
42
Depreciation
24
71
50
32
35
37
35
41
40
-
Income Before Tax
-105
-98
-85
20
99
147
149
259
312
410
Income Tax Expense
14
23
66
19
5
22
82
31
75
25
Net Income
-120
-121
-151
1
94
124
66
227
237
384
Net Profit Margin
85.13%
82.98%
85.76%
85.23%
87.49%
86.09%
90.49%
88.95%
89.76%
88.52%

BeOne Medicines Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
238
198
428
308
1,176
1,415
2,458
3,810
5,343
Gross Profit
-35
-509
357
238
1,011
1,129
2,078
3,216
4,674
Operating Income
-98
-705
-959
-1,657
-1,438
-1,789
-1,207
-568
447
EBITDA
-93
-695
-941
-1,625
-1,392
-1,894
-738
-361
616
Interest Expense
4
-
-
-
-
-
-
-
58
Depreciation
4
10
18
31
46
66
87
171
141
Income Before Tax
-91
-689
-943
-1,618
-1,438
-1,961
-825
-533
416
Income Tax Expense
2
-15
6
10
19
42
55
111
129
Net Income
-93
-673
-948
-1,624
-1,457
-2,003
-881
-644
286
Net Profit Margin
-14.94%
-257.03%
83.38%
77.12%
85.98%
79.77%
84.55%
84.41%
87.49%

BeOne Medicines Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-120
-121
-151
1
94
124
382
228
464
384
Operating Cash Flow
-95
188
75
44
263
402
417
201
664
508
Investing Cash Flow
-111
-133
-93
-121
-66
-49
-38
-45
-94
-35
Financing Cash Flow
23
12
-4
-33
35
961
97
68
62
102
Change in Cash
-189
95
-74
-108
255
1,324
499
243
671
585

BeOne Medicines Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-93
-674
-950
-1,600
-1,413
-2,003
-881
-644
286
Operating Cash Flow
12
-547
-750
-1,283
-1,298
-1,496
-1,157
-140
1,127
Investing Cash Flow
-356
-637
554
-3,168
640
1,077
60
-548
-276
Financing Cash Flow
490
1,690
85
5,202
3,636
-18
416
193
1,059
Change in Cash
152
501
-119
769
2,992
-507
-689
-547
1,970

Global Institutional Holdings in BeOne Medicines

Check out the Institutions with significant holdings in BeOne Medicines.

Funds
Holdings
JOHN OYLER
43.14%
Xiaodong Wang
8.71%
Baker Bros. Advisors Lp
8.18%
Felix Baker
8.02%
Theofanis Kolokotrones
4.47%

BeOne Medicines News & Key Events

  • img

    Today's Timeline - 04 November

    Wed, 02:32 PM

    -

    BeOne Medicines to report Q3 earnings on November 6, with strong analyst expectations.

    Wed, 07:45 PM

    -

    FDA grants Priority Review for BRUKINSA combination therapy for mantle cell lymphoma.

Insights on BeOne Medicines

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    BeOne Medicines Ltd. has shown strong growth in its net profit over the last four quarters. The company's net profit has increased from $66.50 million to $384.70 million, with an average quarterly growth rate of 37.7%. This consistent upward trend indicates positive performance and financial health for the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    BeOne Medicines Ltd. American Depositary Shares have shown consistent growth in revenue over the last 7 quarters. Revenue increased from $1.11 billion to $1.88 billion, resulting in an average rise of 8.3% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, ONC stock has moved up by 19.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 801.8% return, outperforming this stock by 787.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 191.8% return, outperforming this stock by 71.6%

About BeOne Medicines

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
OrganisationBeOne Medicines
HeadquartersAeschengraben 27, Basel, PA, 4051, CH
IndustryBiotechnology
CEOJohn V. Oyler

Key Management of BeOne Medicines

Name

Title

Ms. Liza Heapes

Head of Investor Relations

Mr. Graham Hardiman

Global Head of Human Resources

Dr. Xiaodong Wang Ph.D.

Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder

Mr. Marcello Damiani

Chief Technology Officer

Mr. Chan Lee

General Counsel, Senior VP & Corporate Secretary

Mr. Titus B. Ball

VP & Chief Accounting Officer

Ms. Eleanor Duff Ph.D.

Senior VP & Head of Corporate Communications

Mr. Luo Lusong Ph.D.

Head of External Innovation & Senior VP

Mr. John V. Oyler

Co-Founder, Executive Chairman & CEO

Mr. Wang Lai Ph.D.

President and Global Head of Research & Development

FAQs

What is BeOne Medicines share price today?

BeOne Medicines share price today is $413.08 as on . BeOne Medicines share today touched a day high of $418.35 and a low of $411.87.

What is the 52 week high and 52 week low for BeOne Medicines share?

BeOne Medicines share touched a 52 week high of $424.73 on and a 52 week low of $253.95 on . BeOne Medicines stock price today i.e. is trending at $413.08,which is 2.74% down from its 52 week high and 62.66% up from its 52 week low.

What is BeOne Medicines's market capitalisation today?

BeOne Medicines market capitalisation is $0.05T as on .

How to invest in BeOne Medicines Stock (ONC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for BeOne Medicines on INDmoney app. Click on Buy button.

What is the minimum amount required to buy BeOne Medicines Stock (ONC) from India?

Indian investors can start investing in BeOne Medicines (ONC) shares with as little as ₹93.92250061035156 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.23 in BeOne Medicines stock (as per the Rupee-Dollar exchange rate as on ). Based on BeOne Medicines share’s latest price of $413.08 as on November 17, 2026 at 2:04 am IST, you will get 0.0242 shares of BeOne Medicines. Learn more about fractional shares .